Cladribine Regimen For Treating Multiple Sclerosis
Patent No. EP4070800 (titled "Cladribine Regimen For Treating Multiple Sclerosis") was filed by Merck Serono on Dec 20, 2005. The application was issued on Oct 16, 2024.
Patent Summary
A method for treating multiple sclerosis using oral cladribine, comprising an induction treatment of 1-7 days of cladribine administration per month for 2-4 months, followed by a 2-10 month cladribine-free period, and then a maintenance treatment of 1-7 days of cladribine administration per month for 2-4 months. The treatment can be repeated for a total duration of 2-4 years.
Patent Family
Patent Oppositions
Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.
Dossier Documents
The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.
Date
Description
Get instant alerts for new documents
EP4070800
- Application Number
- EP22166610A
- Filing Date
- Dec 20, 2005
- Status
- Granted And Under Opposition
- Sep 13, 2024
- Publication Date
- Oct 16, 2024
- External Links
- Slate, Register , Google Patents